Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617

被引：5

作者：

Wei, Xiao ^{[1
]}

Schlenkhoff, Carl ^{[1
]}

Sopora, Claudia ^{[2
]}

Essler, Markus ^{[1
]}

Ahmadzadehfar, Hojjat ^{[1
]}

机构：

[1] Univ Hosp Bonn, Dept Nucl Med, Sigmund Freud Str 25, D-53127 Bonn, Germany

[2] Private Off Urol, Bonn, Germany

来源：

CLINICAL NUCLEAR MEDICINE | 2016年 / 41卷 / 11期

关键词：

liver metastases; PSMA; radioligand therapy; hormone refractory; prostate cancer; ABIRATERONE ACETATE; SURVIVAL; CHEMOTHERAPY;

D O I：

10.1097/RLU.0000000000001358

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

An 81-year-old castrate-resistant prostate cancer man with multiple lymph node, bone, and hepatic metastases received four cycles of Lu-177-PSMA-617 treatments at our department from May to December 2015. All of his liver metastases showed PSMA expression in Ga-68-PSMA PET performed before the first cycle. Under this therapy, all of the metastases showed significant regression in size and PSMA expression over time.

引用

页码：894 / +

页数：2

共 9 条

[1] Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer [J].

Ahmadzadehfar, Hojjat ;

Eppard, Elisabeth ;

Kuerpig, Stefan ;

Fimmers, Rolf ;

Yordanova, Anna ;

Schlenkhoff, Carl Diedrich ;

Gaertner, Florian ;

Rogenhofer, Sebastian ;

Essler, Markus .

ONCOTARGET, 2016, 7 (11) :12477-12488

[2] Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study [J].

Ahmadzadehfar, Hojjat ;

Rahbar, Kambiz ;

Kuerpig, Stefan ;

Boegemann, Martin ;

Claesener, Michael ;

Eppard, Elisabeth ;

Gaertner, Florian ;

Rogenhofer, Sebastian ;

Schaefers, Michael ;

Essler, Markus .

EJNMMI RESEARCH, 2015, 5 :1-8

[3] A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel [J].

Chi, K. N. ;

Kheoh, T. ;

Ryan, C. J. ;

Molina, A. ;

Bellmunt, J. ;

Vogelzang, N. J. ;

Rathkopf, D. E. ;

Fizazi, K. ;

Kantoff, P. W. ;

Li, J. ;

Azad, A. A. ;

Eigl, B. J. ;

Heng, D. Y. C. ;

Joshua, A. M. ;

de Bono, J. S. ;

Scher, H. I. .

ANNALS OF ONCOLOGY, 2016, 27 (03) :454-460

[4] Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy [J].

Etchebehere, Elba C. ;

Araujo, John C. ;

Milton, Denai R. ;

Erwin, William D. ;

Wendt, Richard E., III ;

Swanston, Nancy M. ;

Fox, Patricia ;

Macapinlac, Homer A. ;

Rohren, Eric M. .

CLINICAL NUCLEAR MEDICINE, 2016, 41 (04) :268-273

[5] Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer [J].

Mikah, Phillip ;

Krabbe, Laura-Maria ;

Eminaga, Okyaz ;

Herrmann, Edwin ;

Papavassilis, Philipp ;

Hinkelammert, Reemt ;

Semjonow, Axel ;

Schrader, Andres-Jan ;

Boegemann, Martin .

BMC CANCER, 2016, 16

[6]

RAHBAR K, 2016, J NUCL MED

[7] Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer [J].

Rahbar, Kambiz ;

Bode, Axel ;

Weckesser, Matthias ;

Avramovic, Nemanja ;

Claesener, Michael ;

Stegger, Lars ;

Boegemann, Martin .

CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) :522-528

[8] Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study [J].

Ryan, Charles J. ;

Smith, Matthew R. ;

Fizazi, Karim ;

Saad, Fred ;

Mulders, Peter F. A. ;

Sternberg, Cora N. ;

Miller, Kurt ;

Logothetis, Christopher J. ;

Shore, Neal D. ;

Small, Eric J. ;

Carles, Joan ;

Flaig, Thomas W. ;

Taplin, Mary-Ellen ;

Higano, Celestia S. ;

de Souza, Paul ;

de Bono, Johann S. s ;

Griffin, Thomas W. ;

De Porre, Peter ;

Yu, Margaret K. ;

Park, Youn C. ;

Li, Jinhui ;

Kheoh, Thian ;

Naini, Vahid ;

Molina, Arturo ;

Rathkopf, Dana E. .

LANCET ONCOLOGY, 2015, 16 (02) :152-160

[9] Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy [J].

Scher, Howard I. ;

Fizazi, Karim ;

Saad, Fred ;

Taplin, Mary-Ellen ;

Sternberg, Cora N. ;

Miller, Kurt ;

de Wit, Ronald ;

Mulders, Peter ;

Chi, Kim N. ;

Shore, Neal D. ;

Armstrong, Andrew J. ;

Flaig, Thomas W. ;

Flechon, Aude ;

Mainwaring, Paul ;

Fleming, Mark ;

Hainsworth, John D. ;

Hirmand, Mohammad ;

Selby, Bryan ;

Seely, Lynn ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (13) :1187-1197

← 1 →